

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON
JUNE 19, 2024**

The Board announces that at the AGM held on June 19, 2024, all proposed resolutions as set out in the notice of the AGM were duly passed by the Shareholders by way of poll.

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 19, 2024, all proposed resolutions as set out in the notice of the AGM were duly passed by the shareholders of the Company (the “**Shareholders**”) by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 24, 2024 (the “**Circular**”). The executive Director Dr. Zhisheng Chen and the non-executive Director Dr. Weichang Zhou attended the AGM in person.

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditor of the Company for the year ended December 31, 2023.	1,858,530,387 (99.86%)	2,656,000 (0.14%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
2.	(a) To re-elect Dr. Weichang Zhou as non-executive Director.	1,728,268,404 (92.86%)	132,883,482 (7.14%)
	(b) To re-elect Dr. Yibing Wu as non-executive Director.	1,734,170,812 (93.18%)	126,981,074 (6.82%)
	(c) To re-elect Mr. William Robert Keller as independent non-executive Director.	1,663,244,467 (89.37%)	197,907,419 (10.63%)
	(d) To re-elect Dr. Jue Chen as independent non-executive Director.	1,859,912,107 (99.93%)	1,239,779 (0.07%)
3.	To authorize the Board or any duly authorized Board committee to fix the Directors' remuneration for the year ending December 31, 2024.	1,839,722,747 (98.85%)	21,429,139 (1.15%)
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorize the Board or any duly authorized Board committee to fix their remuneration.	1,839,327,758 (98.83%)	21,824,128 (1.17%)
5.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company (including any sale or transfer of treasury shares).	1,790,244,509 (96.19%)	70,907,377 (3.81%)
6.	To grant a general mandate to the Directors to repurchase the shares of the Company.	1,859,274,386 (99.90%)	1,877,500 (0.10%)
Special Resolution		For	Against
7.	To approve the adoption of the fourth amended and restated memorandum and articles of association of the Company, which contain the proposed amendments to the Existing Memorandum and Articles of Association (as defined in the notice convening the AGM) as set out in Appendix II of the circular of the Company dated May 24, 2024, in substitution for, and to the exclusion of, the Existing Memorandum and Articles of Association.	1,860,954,646 (99.99%)	197,240 (0.01%)

Notes:

- (1) As at the date of the AGM, (i) the total number of Shares in issue was 4,153,106,949; (ii) there were no treasury Shares held by the Company; and (iii) there were 1,810,000 repurchased Shares which are pending cancellation and should be excluded from the total number of Shares in issue for the purpose of the AGM. The Company confirmed that no voting rights of the 1,810,000 repurchased Shares which are pending cancellation have been exercised at the AGM.

Accordingly, the total number of Shares entitling the holders thereof to attend and vote for or against or abstain from voting on all the resolutions proposed at the AGM is 4,151,296,949.

- (2) There were no Shares entitling the holders thereof to attend and abstain from voting in favor of any resolution at the AGM as set out in Rule 13.40 of the Listing Rules.
- (3) As at the date of the AGM, Computershare Hong Kong Trustees Limited, being the trustee (the “**Trustee**”) holding unvested Restricted Shares granted under the Restricted Share Award Scheme and/or the Global Partner Program Share Scheme, held 68,325,739 Shares.

Save for the Trustee who was required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders’ approval under the Listing Rules, no other Shareholder was required to abstain from voting in respect of any resolution at the AGM.

- (4) The Company’s Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, June 19, 2024

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen as executive Director; Dr. Ge Li, Dr. Weichang Zhou, Dr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*